Degenerative Disc Disease (DDD)
0
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Spine BioPharmaNY - New York
2 programsFLDN/A1 trial
Lumbar Interbody Fusion DevicesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
ReGelTecThe ReGelTec HYDRAFIL™ System
Spine BioPharmaLumbar Interbody Fusion Devices
Spine BioPharmaFLD
Clinical Trials (3)
Total enrollment: 990 patients across 3 trials
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
Start: Jan 2025Est. completion: Nov 2028225 patients
N/ARecruiting
Retro Comparison of Subsidence Following Interbody Devices in Lumbar Spine
Start: Aug 2022Est. completion: Jul 2025465 patients
N/ACompleted
Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease
Start: Sep 2008Est. completion: Jul 2018300 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 990 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.